See upside in Ranbaxy Laboratories: Sukhani

See upside in Ranbaxy Laboratories, says Sudarshan Sukhani of s2analytics.com.

Sukhani told CNBC-TV18, "Two days ago I felt that BHEL is probably going to outperform now as compared to L&T and that theme is building up. BHEL is now building the right patterns, it is breaking out. It has done some false breakouts earlier, but given the market sense now I do not think this one is going to be a false breakout. If this is a genuine breakout then BHEL has a lot of steam ahead. When we have a choice between two capital goods majors L&T and BHEL, I think BHEL is more appropriate. The percentage gains here could be much better."
He further added, "Same for Ranbaxy. Here is a stock that is doing nothing, but it is building a base. It has made a head and shoulder pattern, a bullish pattern and is breaking out now. These markets are cyclical. Some stocks are picked up, some sectors are picked up and then dropped while some others are done. So within the pharma sector the ones that have run up a lot may take a backseat again, while stocks like Ranbaxy could probably see a very good run."